Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | BCL6 | P41182 | 15/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31520617 | 0.94 | KDM4E (0.52) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL20569695 | 0.91 | BCL6 (0.55) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL31520616 | 0.91 | BCL6 (0.49) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL29203274 | 0.90 | KDM4E (0.48) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL30232262 | 0.90 | KDM4E (0.48) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL29203270 | 0.90 | KDM4E (0.48) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL20568589 | 0.88 | KDM4E (0.46) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL31520723 | 0.86 | BCL6 (0.48) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL29203204 | 0.86 | KDM4E (0.44) | KDM4EALDH1A1GAAMAPTGFER | |
| SCHEMBL20568866 | 0.84 | CNR2 (0.42) | KDM4EALDH1A1GAAMAPTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-08 | — | — | US | disclosed |
| CN-118561812-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-3630291-B9 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4374858-A2 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-29 | — | — | EP | disclosed |
| CN-111163839-B | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3630291-B1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| EP-3630291-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215801-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | KDM4E 309/4885ALDH1A1 1654/4885GAA 2771/4885 |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | KDM4E 309/4885ALDH1A1 1654/4885GAA 2771/4885 |
| US-12110286-B2 | Benzimidazolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | KDM4E 309/4885ALDH1A1 1654/4885GAA 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.